The trial will enroll patients receiving first-line treatment for HER-2 negative metastatic disease and will combine ASA404 with taxanes

monthly leuprolide in prostate cancer patients during the first year of treatment, with data showing that patients receiving Firmagon had a prostate-specific antigen recurrence rate of 7.7 percent compared to 12.9 percent in the leuprolide arm

Dynavax Technologies Corp., of Berkeley, Calif., said that enrollment has been completed for the first of three cohorts of patients receiving DV-601 hepatitis B therapy in a Phase Ib trial

Patients receiving the Xeloda-containing regimen were significantly less likely to have their cancer spread to another part of the body

Mesoblast Ltd., of Melbourne, Australia, announced successful results from the first 18 patients receiving a bone marrow transplant using umbilical cord blood expanded by the allogeneic Mesenchymal Precursor Cells (MPCs...In patients receiving MPC-expanded cord blood, the median time to neutrophil recovery was 16 days and to platelet recovery 38 days, compared with approximately 30 days and over 90 days, respectively, in published reports of patients transplanted with an unexpanded cord

BioAlliance SA, of Paris, reported results on an epidemiologic study on oropharyngeal candidiasis in oncology showing that, of 2,027 cancer patients, there was a 10 percent prevalence of OPC, and that patients receiving a combination of chemotherapy and radiotherapy were more likely to suffer from OPC (22 percent) that those receiving chemotherapy or radiotherapy alone

Vaccinated with Heplisav, chronic kidney disease patients demonstrated rapid, increased protection against hepatitis B viral infection in fewer doses than patients receiving licensed vaccine

Those findings, presented at the Obesity Society meeting in Washington, add to the top-line data presented earlier this year, which showed a significant weight loss in patients receiving one year of treatment with lorcaserin. (See BioWorld Today, Sept. 21, 2009

Those data were presented at the American College of Gastroenterology meeting in San Diego, along with additional results showing that the majority of Crohn's patients receiving Cimzia in an exploratory trial - designated WELCOME - experienced no hospitalizations and surgical procedures during the course of the 26-week study

The firm said 22 percent of the patients treated with DCVax-Brain have now reached or exceeded the six-year survival mark, compared with the less than 5 percent of patients receiving the standard-of-care treatment who are still alive at five years

Data showed that a higher proportion of patients receiving NT 201 were responders in terms of improvement in the wrist flexors four weeks after treatment

patients receiving sham injections

No patients receiving the low dose of Iluvien experienced IOP increases of 30 mmHg or greater, while 29 percent of the patients receiving the high dose of Iluvien experienced IOP increases of 30 mmHg or greater at some time point

In the six-minute walk test, patients receiving ASM treatment showed an increase on average by more than 91 meters vs

Data showed 43 percent and 44 percent of patients taking two different doses were symptom-free for the two years compared to 16 percent of patients receiving placebo

The study included seven dose cohorts, with a total of 41 patients receiving either placebo or single doses of ARRY-403 ranging from 25 mg to 400 mg...Genmab A/S, of Copenhagen, and GlaxoSmithKline plc, of London, reported top-line results from a Phase II study of Arzerra (ofatumumab) in combination with fludarabine and cyclophosphamide in previously untreated chronic lymphocytic leukemia patients, showing a complete remission rate of 32 percent in patients receiving the 500-mg Arzerra regimen and

Pharmasset Inc., of Princeton, N.J., said preliminary results from a Phase I study showed that PSI-7851, a second-generation nucleotide polymerase inhibitor of hepatitis C virus, demonstrated antiviral activity, with a mean HCV RNA decrease of -0.49 log10 IU/mL, -.61 log10 IU/mL and -1.01 log10 IU/mL in patients receiving once daily doses of 50 mg, 100 mg and 200 mg, respectively, for three days

Some 84.6 percent of study patients receiving one injection of serum-free HSC showed an increase in terminal hair 12 weeks post-injection, with a statistically significant increase in the number of terminal hairs, cumulative hair thickness density and hair thickness mean

The 35-patient trial included 27 patients receiving MAXY-G34 of dosages of 10, 30, 45, 60 or 100 mcg/kg and eight patients receiving Amgen Inc.'s Neulasta (pegfilgrastim) at a fixed dose of 6 mg